Patent intelligence · US
US 10179817
Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
Patent details — US 10179817
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 15, 2019
- Expiration
- Jan 10, 2039
- Applicant
- CytomX Therapeutics, Inc.
- Claims
- 58
- CPC classes
- A61K, A61K2039/505, A61K39/3955, A61K47/6803
Quick answer
US 10179817 (Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof) is held by CytomX Therapeutics, Inc.. Status: granted. Granted Jan 15, 2019. Expires Jan 10, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 58
- CPC classes
- A61K, A61K2039/505, A61K39/3955, A61K47/6803, A61K47/68031, A61K47/68033
More from CytomX Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428470
Compositions containing activatable antibodies
granted -
US 12139543
Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR
granted -
US 12049505
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
granted -
US 11992528
Compositions and methods for conjugating activatable antibodies
granted -
US 11952427
Anti-CD40 antibodies and uses thereof
granted -
US 11890354
Activatable antibodies that bind epidermal growth factor receptor and methods thereof
granted -
US 11884746
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
granted -
US 11867695
Compositions and methods for detecting protease activity in biological systems
granted
Frequently asked questions
What is US patent 10179817?
US 10179817 (Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof) is held by CytomX Therapeutics, Inc.. Status: granted. Granted Jan 15, 2019. Expires Jan 10, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10179817?
CytomX Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 62 pharmaceutical patents for this assignee.
When does US 10179817 expire?
Our index shows an expiration date of Jan 10, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.